

# REVIEW OF DECISIONS

---

BOARD MEETING

22-23 June 2022, Geneva, Switzerland



Reach every child

[www.gavi.org](http://www.gavi.org)

# Decision 1: Consent Agenda: Board Committee Chair Appointments

---

The Gavi Alliance Board:

**Appointed Anne Schuchat** as Chair of the Programme and Policy Committee effective 1 July 2022 and until 31 December 2023.

# Decision 2: Consent Agenda: Board and Committee Member Appointments

---

The Gavi Alliance Board:

- a) **Appointed Deena Schiff** as an Unaffiliated Board Member in the seat currently held by Helen Rees effective 1 July 2022 and until 30 June 2025;
- b) **Appointed Aamer Ikram** of Pakistan as Board Member representing the implementing country constituency in the seat currently held by Faisal Sultan of Pakistan, effective immediately and until 31 December 2023;
- c) **Appointed Won Do-yeon** as Alternate Board Member representing the Republic of Korea on the donor constituency anchored by the United States in the seat currently held by Takeshi Akahori of Japan, effective immediately and until 31 December 2023;
- d) **Appointed** the following to the Governance Committee effective immediately:
  - **Takeshi Akahori** (Board Member) until 31 December 2023
  - **Aamer Ikram** (Board Member) until 31 December 2023
- e) **Appointed** the following to the Audit and Finance Committee effective immediately:
  - **Megan Cain** (Alternate Board Member) until 31 December 2022

# Decision 3: Consent Agenda: Appointment of Judge to Appeals Tribunal

---

The Gavi Alliance Board:

**Appointed** Joan Powers as a member of the Gavi Appeals Tribunal effective immediately for a term of five years.

# Decision 4: Consent Agenda: Investment Committee Charter

---

The Gavi Alliance Board:

**Approved** the amendments to the Gavi Alliance Investment Committee Charter as set out in Annex A to Doc 01e.

# Decision 5: Consent Agenda: COVAX Facility Governance

---

The Gavi Alliance Board:

**Extended** the term of the COVID-19 Vaccination Delivery Support Temporary Steering Committee to end December 2022.

# Decision 6: Consent Agenda: UNICEF Procurement Fees (1/2)

---

The Gavi Alliance Board:

- a) **Approved**, within the overall Partners' Engagement Framework,
  - i. A budget of US\$ 22 million for UNICEF Supply Division fees for the procurement of vaccines and related devices in 2023;
  - ii. A budget of US\$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2023;
  - iii. A budget of US\$ 1.35 million for UNICEF Supply Division fees for the procurement of diagnostics equipment in 2022; and
  - iv. A budget of US\$ 1.35 million for UNICEF Supply Division fees for the procurement of diagnostics equipment for 2023.

# Decision 6: Consent Agenda: UNICEF Procurement Fees (2/2)

---

b) **Noted** that

- i. The proposed fees for 2023 exclude the potential impact of COVID-19 complexities, subject to completion of a review between UNICEF and Gavi; and
- ii. An update will be presented to the Audit and Finance Committee in October 2022.



# Decision 7: Consent Agenda: Funding Policy Review

---

The Gavi Alliance Board:

- a) **Granted** the Secretariat the authority to implement an approach to apply co-financing flexibilities, as described in Annex B to Doc 01e in countries facing severe fiscal distress and/or countries facing a humanitarian crisis, noting that this shift was approved by the Board in December 2019 for incorporation into Gavi's new funding policies; and
- b) **Noted** the Framework for Gavi Funding to Countries.

# Decision 8: Consent Agenda: Innovation Approach for Gavi 5.0

---

The Gavi Alliance Board:

- a) **Approved** the overall innovation approach for Gavi 5.0 as laid out in Annex C to Doc 01e; and
- b) **Approved** US\$ 50 million in additional funding for Health System Strengthening (HSS) in Gavi 5.0 for countries interested in scaling proven innovations to be allocated, in accordance with the Programme Funding Policy, above HSS country ceilings on an exceptional basis.

# Decision 9: Consent Agenda: Malaria Vaccine Implementation Programme

---

The Gavi Alliance Board:

- a) **Approved** an increase in the amount of funds for Phase 2 MVIP activities from US\$ 11.6 million to US\$ 12.25 million by allocating the Phase 1 underspend (US\$ 650,000) to be applied towards the previously approved Phase 2 activities; and
- b) **Noted** that any underspend from the Phase 2 activities are to be returned to Gavi in accordance with the terms of the grant agreement.

# Decision 10: Financial Update, including forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations to be made to the Programme and Policy Committee and concluded that the recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy;
- b) **Approved** the updated Financial Forecast for the Gavi 5.0 (2021-2025) Strategic Period as set out in Section 2 and Annex B to Doc 04;
- c) **Approved** the updated Financial Forecast for COVAX AMC (2020-2023) as set out in Section 3 and Annex D to Doc 04;
- d) **Approved** the Financial Forecast for the Gavi 6.0 (2026-2030) Strategic Period as set out in Section 2 and Annex C to Doc 04 noting that only existing programmes have been forecast and the forecast has been prepared to enable the Secretariat to allot funding to these programmes in accordance with the Programme Funding Policy and does not prejudice future donor contributions or future investment decisions.

# Decision 11: COVAX: Key Strategic Issues

The Gavi Alliance Board:

- a) **Approved** the continued administration of the COVAX Facility by Gavi in 2023;
- b) **Delegated** to the CEO, with reporting to the Board, the authority to approve flexibility to adapt programmes based upon updated SAGE recommendations for COVID-19 (such as on vaccine use, additional boosters, the need for variant-adapted vaccines), contingent on available supply and funding;
- c) Informed by the interim approach outlined in Annex A to Doc 05, **approved** future paediatric support (July 2022 onwards) that supports continued limited provision of paediatric doses, based on country plans, targets and demographics, with safeguards related to restoring and maintaining routine immunisation and continued COVID-19 vaccine prioritisation, according to WHO recommendations, in particular of high priority group coverage, and considering sustainability as well as any adverse impact on immunisation programmes.

# Decision 12: Review of Fragility, Emergencies, Refugees Policy

---

The Gavi Alliance Board:

- a) **Approved** the revised Fragility, Emergencies and Displaced Populations Policy attached in Annex A to Doc 07;
- b) **Granted** the Gavi Secretariat Emergency Declaration Team<sup>1</sup> the authority to waive the requirement for independent review for new funding as per the Programme Funding Policy. This will be only in time-sensitive situations, with the objective to swiftly disburse funding in acute emergencies on a no regrets basis, noting that the framework including guardrails under which the Emergency Declaration Team can waive the requirements for independent review will be defined by the Secretariat in the operational guidelines, along with requirements for retrospective reporting to governance bodies including the Programme and Policy Committee and the Audit and Finance Committee.

---

<sup>1</sup> The Emergency Declaration Team is composed of MD Finance & Operations and MD Country Programmes, however in decisions requiring waiving independent review, the Director of Strategy, Funding & Performance will also be part of the decision making, given their role as second line of defence for Gavi's review process.

# Decision 13: Gavi's Approach to Engagement with Former and Never-Eligible Middle-Income Countries (MICs) (1/2)

The Gavi Alliance Board:

- a) **Approved** updating the list of lower middle income countries eligible for support under the MICs Approach in line with 2021, 2022 and 2023 World Bank GNI data released in 2022, 2023 and 2024 respectively;
- b) **Approved** the proposed intervention, secretariat resourcing, and funding approval pathways as per Annex B to Doc 09;
- c) **Approved** extending the implementation time from until June 2022 to until the end of December 2025 for use of the US\$ 20 million for targeted support previously approved by the Board in June 2020 for former Gavi-eligible countries;
- d) **Approved** the rules-based approach to supporting eligible MICs that meet the conditions to receive dedicated fragility support as outlined in Annex C to Doc 09.

## Decision 13: Gavi's Approach to Engagement with Former and Never-Eligible Middle-Income Countries (MICs) (2/2)

---

Noting that a GNI classification is not available for Venezuela, and that there is a national and regional threat to immunisation coverage, and further to additional consultations with relevant partners on a best estimate of GNI

e) **Agreed** that Venezuela be treated as eligible under the MICs Approach.



# Board Meetings 2023

---

Board Retreat: 29-30 March 2023

Board Meeting: 28-29 June 2023

Board Meeting: 6-7 December 2023

# Thank you

---

